| Name | Ranolazine dihydrochloride |
| Description | Ranolazine dihydrochloride (Ranolazine 2HCl) , an antianginal agent, can treat arrhythmia via a novel mechanism of action (inhibition of the late phase of the inward sodium current), and do not affect blood pressure or heart rate. |
| In vitro | Ranolazine (5 mM and 10 mM) reversibly shortened the duration of twitch contractions and abolished postcontractions.Ranolazine bound more to sodium channels in the inactivated state. In cardiomyocytes, selective inhibition of late I (sodium) by Ranolazine reduced sodium-dependent calcium overload and attenuated ventricular repolarization and contraction, which correlated with abnormalities in heart failure and ischemia/reperfusion injury. In dog left ventricular myocytes, in a concentration-dependent manner Ranolazine was able to reversibly shorten myocyte action potential duration in response to 0.25/0.5 Hz stimulation. |
| In vivo | Ranolazine (5 mM and 10 mM) reversibly shortened the duration of twitch contractions and abolished postcontractions.Ranolazine bound more to sodium channels in the inactivated state. In cardiomyocytes, selective inhibition of late I (sodium) by Ranolazine reduced sodium-dependent calcium overload and attenuated ventricular repolarization and contraction, which correlated with abnormalities in heart failure and ischemia/reperfusion injury. In dog left ventricular myocytes, in a concentration-dependent manner Ranolazine was able to reversibly shorten myocyte action potential duration in response to 0.25/0.5 Hz stimulation. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 45 mg/mL (89.92 mM)
H2O : 50.1 mg/mL (100 mM)
|
| Keywords | Calcium Channel | Ranolazine Dihydrochloride | RS43285 | Autophagy | RS-43285 | Sodium Channel | CVT-303 | Inhibitor | Ranolazine | Ranolazine dihydrochloride | inhibit | Ca2+ channels | CVT303 | Na+ channels | Ca channels | Na channels | CVT 303 |
| Inhibitors Related | Stavudine | Phenytoin sodium | Sodium 4-phenylbutyrate | L-Ascorbic acid | Hydroxychloroquine | Guanidine hydrochloride | Taurine | Paeonol | Naringin | Gefitinib |
| Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Inhibitor Library | Neuroprotective Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max |
United States
